PAHC Stock Surges on Q4 Earnings & Revenue Beat, Gross Margin Down

Phibro Animal Health (PAHC) delivered a strong close to fiscal 2025, reporting Q4 adjusted EPS of $0.57 and net sales of $378.7 million, both significantly exceeding consensus estimates and marking substantial year-over-year growth. This outperformance was primarily driven by a 53% surge in its Animal Health segment, fueled by the successful integration of the Zoetis MFA portfolio and robust demand across product lines. The positive results, which also saw full-year figures surpass expectations, prompted an 18% after-hours stock rally and underpin the company's optimistic fiscal 2026 guidance, projecting net sales of $1.43-$1.48 billion and adjusted EPS of $2.52-$2.70, both above current analyst consensus, despite a noted contraction in gross margin.

Analysis

Phibro Animal Health (PAHC) reported an exceptionally strong fourth quarter for fiscal 2025, significantly outperforming market expectations and triggering an 18% after-hours share price increase. The company delivered an adjusted EPS of 57 cents, a 39% year-over-year increase and 9.62% above the Zacks Consensus Estimate, on revenues of $378.7 million, which grew 38.6% and beat estimates by 4.86%. This performance was overwhelmingly driven by the Animal Health segment, where sales surged 53%, fueled by a 77% rise in medicated feed additives (MFAs) that included $94.5 million in incremental revenue from the acquired Zoetis MFA portfolio. While the Mineral Nutrition segment showed modest 3% growth and missed internal forecasts, the overall momentum is robust. A key point of concern is the 287 basis point contraction in gross margin to 29.1%, attributed to a 44.5% spike in the cost of goods sold, although this was offset at the operating level by an 82.2% profit increase and a 213 bps margin expansion. The company's optimistic fiscal 2026 guidance, projecting 12% sales growth and 25% adjusted EPS growth, is notably above current analyst consensus, signaling strong management confidence in sustaining this trajectory.

Key Decisions for Investors

• Given the substantial earnings beat, robust forward guidance exceeding consensus, and strong market reaction, investors should consider the stock's positive momentum, driven primarily by the successful integration of the Zoetis portfolio.
• It is critical to monitor gross margins in subsequent quarters, as the 287 bps contraction due to rising costs represents a key risk to profitability, even with the current expansion in operating margin.
• Investors should scrutinize the company's cash position, noting the decline in cash and short-term investments from $114.6 million to $77 million, and look for improvements in operating cash flow in fiscal 2026.
• Evaluate the sustainability of the Animal Health segment's growth, focusing on organic performance metrics to ensure momentum continues beyond the initial uplift from the recent acquisition.